Short answer
Oric Pharmaceuticals, Inc. (ORIC) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$33M
- +5.7% YoY · +10.4% QoQ
- EPS (diluted)
- −$0.31
- +36.7% YoY · +34.0% QoQ
Source: XBRL data from the Oric Pharmaceuticals, Inc. (ORIC) Q3 2025 10-Q on SEC EDGAR. USD.
Oric Pharmaceuticals, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Market conditions risk of banking insolvency triggered by 2023 Silicon Valley Bank receivership causing temporary funds inaccessibility
- Most material update: Net loss $99M for nine months ended Sept 30, 2025; accumulated deficit $661.7M, reflecting ongoing significant losses
- Regulatory risk: FDA, EMA unpredictable approval processes; delays from Project Optimus dose optimization reform impacting oncology product candidates
- Operational risk: Dependence on timely clinical trial completion and patient enrollment amid ongoing global pandemic disruptions affecting near-term progress
- Financial risk: Cash $413M as of Sept 30, 2025, funding operations into second half of 2028, with potential capital needs earlier due to market uncertainties
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Oric Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.